EXHIBIT 10.25
[MEDIMMUNE LOGO HERE]
AMENDMENT
This Amendment, effective on the last date of signature below, modifies
and amends the Collaboration and License Agreement dated effective April 19,
2001 (the "Agreement"), by and between Genaera Corporation ("GENAERA") and
MedImmune, Inc. ("MEDIMMUNE").
WITNESSETH
WHEREAS, MEDIMMUNE and GENAERA desire to amend the Agreement in order
to modify the research plan proposed thereunder;
NOW THEREFORE, in consideration of the promises and of the mutual
covenants and agreements herein set forth, the parties hereto agree as follows:
1. Appendix D of the Agreement is hereby amended by deleting it
in its entirety and replacing it with the Revised Joint R&D
Program ("Exhibit I") attached hereto and incorporated by
reference.
2. The Revised Joint R&D Program will be re-assessed in April
2002 and revised accordingly. Priority will given to the
Primary Goals, with emphasis on Primary Goal I (in vivo
bioassays). Secondary Goals will be addressed if Primary
Goals are complete and resources allow.
This Amendment and the Agreement set forth the entire agreement and
understanding between the parties as to the subject matter thereof and
supersedes all prior agreements and understandings in this respect. There shall
be no amendments or modifications to this Amendment or the Agreement, except by
a written document which is signed by both parties.
IN WITNESS WHEREOF, the parties have each caused this Amendment to be
signed and delivered by its duly authorized officer or representative as
indicated below.
MEDIMMUNE GENAERA
By: /s/ Xxxxx Xxxxxx, Ph.D. By: /s/ Xxx X. Xxxxxx, M.D.
-------------------------------- -----------------------
Name: Xxxxx Xxxxxx, Ph.D. Name:
Title: Vice President, Research Title:
Date: 1/14/02 Date: 1/08/02
------------- -------------
1
